Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Jade Biosciences (Nasdaq: JBIO) closed a public offering of 11,500,000 common shares, including 1,500,000 from full exercise of underwriters’ option, at $15.00 per share.
The deal generated $172.5 million in gross proceeds to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, and general corporate purposes.
Positive
- Public offering raises $172.5 million in gross proceeds
- Sale of 11.5 million new shares fully subscribed including option
- Proceeds earmarked for clinical trials, preclinical work, and manufacturing
- Additional funding supports R&D, capital expenditures, and working capital
Negative
- Issuance of 11.5 million new shares increases total share count
News Market Reaction – JBIO
In the Jun 8 session, JBIO declined 11.57%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Offering priced | Neutral | +0.8% | Pricing of 10,000,000-share offering at $15 with defined use of proceeds. |
| Jun 03 | Offering proposed | Neutral | +0.8% | Announcement of proposed underwritten offering and potential pre-funded warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent equity offering headlines have coincided with modestly positive price reactions around +0.85%, indicating the market has so far absorbed dilution-related news relatively well.
In late May and early June 2026, Jade Biosciences combined positive clinical updates with significant financing activity. Earlier, the company reported encouraging Phase 1 data for JADE101 and initiated a Phase 1 trial for JADE201. More recently, it announced a proposed and then priced underwritten public offering, both tagged as “offering,” with average next-day moves around +0.85%. Today’s closing announcement completes that capital-raising sequence under the existing shelf.
Key Terms
underwriters’ option financial
public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
book-running managers financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of
Jade intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and investments, to fund clinical trials, preclinical studies, and manufacturing in support of its programs, as well as for additional research and development activities, capital expenditures, working capital and other general corporate purposes.
Jefferies, TD Cowen and UBS Investment Bank acted as joint book-running managers for the offering. LifeSci Capital acted as passive book-running manager for the offering. BTIG acted as a lead manager for the offering.
The securities described above were offered by Jade pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on May 15, 2026. A final prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC. The offering was made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; and UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, or by email at ol-prospectus-request@ubs.com. Electronic copies of the final prospectus supplement and accompanying prospectus are available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Jade Biosciences, Inc.
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Forward Looking Statements
Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, our expectations regarding the anticipated use of net proceeds from the offering. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market conditions, as well as the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its subsequent filings). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.
Jade Biosciences Contact
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
